Introduction {#s1}
============

Malaria is an ancient and deadly scourge of humanity, with hundreds of millions of people infected by *Plasmodium* malaria parasites and more than 600,000 deaths each year ([@bib59]). Substantial progress has been made in reducing the global malaria burden, due in part to the success of artemisinin-based combination drug therapies (ACTs). Recent identification of artemisinin-tolerant parasites in southeast Asia, however, has raised concerns that the broad potency of ACTs against all parasite strains may be waning, which could lead to a resurgence in malaria deaths ([@bib13]; [@bib1]). These concerns motivate continued efforts to deepen understanding of basic parasite biology in order to identify new drug targets and facilitate development of novel therapies.

Heme is a ubiquitous biological cofactor required by nearly all organisms to carry out diverse redox biochemistry ([@bib39]). Heme metabolism is a dominant feature during *Plasmodium* infection of erythrocytes, the most heme-rich cell in the human body and the stage of parasite development that causes all clinical symptoms of malaria. Parasites sequester and biomineralize the copious heme released during large-scale hemoglobin digestion in their acidic food vacuole ([@bib55]; [@bib44]); they also require heme as a metabolic cofactor for cytochrome-mediated electron transfer within mitochondria ([@bib35]; [@bib55]; [@bib44]).

Sequencing of the *Plasmodium falciparum* genome over a decade ago and subsequent studies have revealed that parasites encode and express all of the conserved enzymes for a complete heme biosynthesis pathway ([Figure 1A](#fig1){ref-type="fig"}), but the role and properties of this pathway have been the subject of considerable confusion and uncertainty ([@bib15]; [@bib55]; [@bib44]). This pathway was originally proposed to be essential for blood-stage parasite development and thus a potential drug target ([@bib52]), as host heme was thought to be inaccessible for parasite utilization in mitochondria. Recent studies, however, have clarified that de novo heme synthesis is not required by intraerythrocytic parasites and therefore is unlikely to be a viable target for therapeutic inhibition ([@bib32]; [@bib21]). The parasite-encoded ferrochelatase (FC) can be knocked out to ablate heme biosynthesis but parasite growth is unaffected, suggesting that parasites can scavenge host heme to satisfy metabolic requirements during blood-stage infection.10.7554/eLife.09143.003Figure 1.Exogenous ALA stimulates protoporphyrin IX (PPIX) biosynthesis in Plasmodium-infected erythrocytes.(**A**) Schematic depiction of the heme biosynthesis pathway in *Plasmodium falciparum* parasites. Enzymes abbreviations are in red and pathway substrates and intermediates are in black: ALAS (aminolevulinic acid synthase), ALAD (aminolevulinic acid dehydratase), PBGD (porphobilinogen deaminase), UROS (uroporphyrinogen synthase), UROD (uroporphyrinogen decarboxylase), CPO (coproporphyrinogen III oxidase), PPO (PPIX oxidase), FC (ferrochelatase). For simplicity, all organelles are depicted with single membranes. Succinylacetone (SA) inhibits ALAD. (**B**) Bright field and fluorescence microscopy images of untreated and 200 µM aminolevulinic acid (ALA)-treated parasites. Fluorescence images were acquired with a Zeiss filter set 43 HE (excitation 537--562 nm, emission 570--640 nm). (**C**) Growth of asynchronous 3D7 parasites in the presence or absence of 200 µM ALA and 50 µM SA, with 2-min exposures to white light on an overhead projector on days 0--2. Parasitemia (percentage of total erythrocytes infected with parasites) as a function of time was fit with an exponential growth equation.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.003](10.7554/eLife.09143.003)10.7554/eLife.09143.004Figure 1---figure supplement 1.Fluorescence excitation and emission spectrum of PPIX in aqueous buffer.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.004](10.7554/eLife.09143.004)10.7554/eLife.09143.005Figure 1---figure supplement 2.Transmission electron microscopy images of untreated and 500 µM ALA-treated *P. falciparum*-infected erythrocytes after light exposure on an overhead projector light box.The white arrow identifies the digestive vacuole. Scale bar equals 1 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.005](10.7554/eLife.09143.005)10.7554/eLife.09143.006Figure 1---figure supplement 3.ALA dose dependence of photosensitivity by blood-stage Plasmodium parasites.Asynchronous parasites were cultured in the indicated concentration of ALA and exposed to 2 min light daily. Parasitemia was measured after 48 hr and normalized to a reference culture grown without ALA.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.006](10.7554/eLife.09143.006)10.7554/eLife.09143.007Figure 1---figure supplement 4.Giemsa-stained blood smear of *P. falciparum* culture after 3 days of treatment with 200 µM ALA and 2-min daily light exposure on an overhead projector light box.Black arrows identify dead parasite remnants.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.007](10.7554/eLife.09143.007)

Here we use chemical and physical probes to decipher the role of upstream enzymes in heme biosynthesis by parasite-infected erythrocytes. Contrary to simple predictions, genetic disruption of the parasite porphobilinogen deaminase (PBGD) and coproporphyrinogen III oxidase (CPO) had no effect on the ability of *Plasmodium*-infected erythrocytes to convert exogenous aminolevulinic acid (ALA) into heme, as monitored by mass spectrometry and photodynamic imaging of porphyrin intermediates. Biochemical fractionation revealed that vestigial host enzymes remaining in the erythrocyte cytoplasm contribute to ALA-stimulated heme biosynthesis, explaining why disruption of parasite enzymes had no effect on biosynthetic flux. We used small-molecule probes to show that ALA uptake by erythrocytes, which are normally impermeable to ALA, requires the parasite nutrient-acquisition pathways established after invasion. Finally, we show that latent host enzyme activity can be exploited for antimalarial photodynamic therapy (PDT) using (1) ALA to stimulate production of the phototoxic intermediate protoporphyrin IX (PPIX), (2) luminol-based chemiluminescence to photoactivate PPIX cytotoxicity within infected erythrocytes, and (3) luminol stimulation by combinatorial low-dose artemisinin.

Results {#s2}
=======

Exogenous ALA stimulates heme biosynthesis and photosensitizes parasites {#s2-1}
------------------------------------------------------------------------

Production of 5-ALA by ALA synthase (ALAS) is the regulated step in heme biosynthesis. Exogenous ALA bypasses this step and stimulates biosynthetic flux, leading to accumulation of the final intermediate, PPIX, since conversion of PPIX to heme by FC becomes rate limiting ([@bib22]). PPIX is fluorescent ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) and its cellular accumulation can be directly visualized by fluorescence microscopy using a phenomenon called 'photodynamic imaging' that has been exploited for visualizing cancerous tumor boundaries during surgical resection ([@bib5]).

Prior work indicated that exogenous ALA stimulates PPIX production in *P. falciparum* parasites ([@bib46]; [@bib21]). We therefore posited that ALA treatment could serve as a probe of heme biosynthesis activity in *Plasmodium*-infected erythrocytes by enabling direct visualization of PPIX production and the cellular consequences of light activation. Untreated parasites imaged on an epifluorescence microscope display only background auto-fluorescence from hemozoin crystals in the parasite digestive vacuole ([Figure 1B](#fig1){ref-type="fig"}). Parasites grown in 200 µM ALA, however, display bright red fluorescence distributed throughout the infected erythrocyte, as expected for accumulation of PPIX ([Figure 1B](#fig1){ref-type="fig"}).

PPIX is also known to generate cytotoxic reactive oxygen species when photo-illuminated, owing to formation of an excited triplet state that can undergo collisional energy transfer with ground state triplet oxygen to produce highly reactive singlet oxygen ([@bib5]). The ability to kill ALA-treated cells by light activation of accumulating PPIX has been exploited to selectively target cancerous tumors via a strategy known as \'photodynamic therapy\' ([@bib22]; [@bib5]).

The cytotoxic effects of light-activating PPIX were readily apparent by monitoring the motion of hemozoin crystals that dynamically tumble within the digestive vacuole of individual parasites. Although the origin and physiological significance of this motion remain unknown, hemozoin dynamics serve as an internal biomarker of food vacuole integrity and parasite viability ([@bib44]). Hemozoin motion in untreated parasites was unaffected by exposure to light that overlaps the excitation wavelength of PPIX ([Videos 1, 2](#video1 video2){ref-type="other"}). In contrast, the hemozoin dynamics in ALA-treated parasites were rapidly ablated by light ([Videos 3, 4](#video3 video4){ref-type="other"}). Ultra-structural analysis by electron microscopy revealed a loss of electron density within the digestive vacuole of ALA-treated and illuminated parasites ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), suggesting disruption of the food vacuole membrane and outward diffusion of the vacuolar protein contents. These changes are consistent with a photodynamic mechanism of PPIX-mediated generation of reactive oxygen species that cause pleiotropic cytotoxic damage, including loss of lipid bilayer integrity.Video 1.Hemozoin dynamics in the digestive vacuole of untreated parasites prior to light exposure.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.008](10.7554/eLife.09143.008)10.7554/eLife.09143.008Video 2.Hemozoin dynamics in the digestive vacuole of untreated parasites after light exposure.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.009](10.7554/eLife.09143.009)10.7554/eLife.09143.009Video 3.Hemozoin dynamics in the digestive vacuole of 200 µM ALA-treated parasites prior to light exposure.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.010](10.7554/eLife.09143.010)10.7554/eLife.09143.010Video 4.Hemozoin dynamics in the digestive vacuole of 200 µM ALA-treated parasites after light exposure.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.011](10.7554/eLife.09143.011)10.7554/eLife.09143.011

To test the effects of these changes on bulk parasite culture, we monitored the growth of untreated vs ALA-treated parasites over several days with 2-min daily exposures to broad-wavelength white light on an overhead projector light box. Whereas untreated parasite cultures grew normally in the presence of light, the growth of ALA-treated cultures was strongly attenuated by light ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}), consistent with a prior report ([@bib46]). Microscopic examination by blood smear revealed that ALA-treated cultures predominantly contained karyolytic and pyknotic parasites ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}), indicative of widespread cell death. The photosensitivity of parasite growth in ALA was fully rescued by 50 µM succinylacetone (SA), an ALA dehydratase (ALAD) inhibitor shown in previous work to substantially reduce PPIX biosynthesis from ALA in parasite-infected erythrocytes ([@bib32]; [@bib21]). This chemical rescue confirmed that parasite photosensitivity in ALA requires biosynthetic conversion of ALA to PPIX.

Stable disruption of parasite enzymes or the apicoplast organelle does not affect heme biosynthesis from ALA {#s2-2}
------------------------------------------------------------------------------------------------------------

The constituent enzymes of the parasite\'s heme biosynthesis pathway are distributed between three sub-cellular compartments: the mitochondrion, the cytoplasm, and the chloroplast-like but non-photosynthetic apicoplast organelle ([Figure 1A](#fig1){ref-type="fig"}) ([@bib55]). Prior work indicated that the parasite FC gene could be knocked out, resulting in a complete ablation of de novo heme synthesis but with no effect on parasite growth ([@bib32]; [@bib21]). This observation provided strong evidence that parasites do not require heme biosynthesis for growth in erythrocytes, where they can presumably scavenge abundant host heme to meet metabolic needs. We therefore reasoned that upstream enzymes in the parasite-encoded heme biosynthesis pathway should also be amenable to genetic disruption and that such ablations would block production of PPIX from exogenous ALA ([Figure 1A](#fig1){ref-type="fig"}) and thus prevent parasite photosensitivity.

We successfully disrupted the parasite genes encoding the apicoplast-targed PBGD ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) and the cytosolic CPO ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) using single-crossover homologous recombination to truncate the open reading frame for each gene. Southern blot and polymerase chain reaction (PCR) analysis confirmed correct integration and gene disruption in clonal parasite lines ([Figure 2---figure supplements 3, 4](#fig2s3 fig2s4){ref-type="fig"}). Contrary to simple predictions, however, these genetic disruptions had no effect on the ability of parasite-infected erythrocytes to incorporate ^13^C-labelled ALA into heme, PPIX, or coproporphyrinogen III (CPP) ([Figure 2A](#fig2){ref-type="fig"}), as monitored by a previously developed LC-MS/MS assay ([@bib21]), and clonal growth of both parasite lines remained fully photosensitive in ALA ([Figure 2B,C](#fig2){ref-type="fig"}).10.7554/eLife.09143.012Figure 2.Heme biosynthesis in infected erythrocytes persists despite disruption of parasite enzymes or the apicoplast.(**A**) Liquid chromatography-tandem mass spectrometry (LC-MS/MS) detection of ^13^C-labelled heme, PPIX, and coproporphyrinogen III (CPP) in parasites grown in 200 µM 5-\[^13^C~4~\]-ALA. Parasites were extracted in dimethyl sulfoxide (DMSO), supplemented with deuteroporphyrin as an internal standard, and analyzed by LC-MS/MS. Integrated analyte peak areas were normalized to PPIX in each sample. RBC: uninfected red blood cells, WT: parental clone 3D7, IPP/dox: isopentenyl pyrophosphate/doxycycline-treated 3D7 parasites. (**B**, **C**) Growth of asynchronous ∆PBGD (**B**) and ∆CPO (**C**) 3D7 parasites in the presence or absence of 200 µM ALA, with 2-min light exposures on an overhead projector on days 0--2. WT growth was fit to an exponential equation. (**D**) Bright field and fluorescence images of live 3D7 parasites expressing ALAD-GFP from a plasmid before or after 2-week treatment with IPP and doxycycline. (**E**) Growth of asynchronous IPP/doxycycline-treated parasites in the presence or absence of 200 µM ALA and 50 µM SA, with 2-min light exposures on an overhead projector on days 0--2.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.012](10.7554/eLife.09143.012)10.7554/eLife.09143.013Figure 2---figure supplement 1.Immunofluorescence microscopy (IFM) images of fixed 3D7 parasites expressing full-length PBGD tagged at its endogenous locus with C-terminal GFP confirm targeting of the native protein to the parasite apicoplast.Parasites were stained with αGFP and αACP (ACP, apicoplast marker).**DOI:** [http://dx.doi.org/10.7554/eLife.09143.013](10.7554/eLife.09143.013)10.7554/eLife.09143.014Figure 2---figure supplement 2.Fluorescence microscopy images of live 3D7 parasites episomally expressing full-length CPO with a C-terminal GFP tag confirm protein localization to the parasite cytoplasm.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.014](10.7554/eLife.09143.014)10.7554/eLife.09143.015Figure 2---figure supplement 3.Disruption of the *P. falciparum* PBGD gene (PF3D7_1209600) by single-crossover homologous recombination.(**A**) Schematic depiction of the PBGD gene locus before and after incorporation of the donor plasmid via single-crossover recombination. Red arrows indicate the primers used to selectively polymerase chain reaction (PCR) amplify either the intact WT or disrupted ∆PBGD locus. SacI and BglII were used to digest the donor plasmid and genomic DNA (gDNA) of WT and ∆PBGD parasites to give the expected fragment sizes indicated in parentheses for hybridization to a PBGD bp 601--960 oligonucleotide probe. (**B**) PCR analysis of gDNA from WT and ∆PBGD clones using the primers indicated in (**A**) to selectively amplify the 1.3 kb WT gene or the 960 bp truncated gene. (**C**) Southern blot analysis of gDNA from 3D7 WT and ∆PBGD clonal parasites after digestion with SacI and BglII, hybridization with a PBGD bp 601--960 oligonucleotide probe, and detection using the Amersham AlkPhos Labeling and CDP-Star chemiluminescent reagents. (**D**) Homology model of *P. falciparum* PBGD (human PBGD template structure 3EQ1) to indicate the portion of the protein retained (cyan) or lost (green) by single-crossover truncation. The deleted sequence comprises half of the active site binding pocket, identified by the dipyrromethane cofactor shown in red.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.015](10.7554/eLife.09143.015)10.7554/eLife.09143.016Figure 2---figure supplement 4.Disruption of the *P. falciparum* CPO gene (PF3D7_1142400) by single-crossover homologous recombination.(**A**) Schematic depiction of the CPO gene locus before and after incorporation of the donor plasmid via single-crossover recombination. Red arrows indicate the primers used to selectively PCR-amplify either the intact WT or disrupted ∆CPO locus. XhoI and KpnI were used to digest the donor plasmid and gDNA of WT and ∆CPO parasites to give the expected fragment sizes indicated in parentheses for hybridization to a CPO bp 610--1080 oligonucleotide probe. (**B**) PCR analysis of gDNA from WT and ∆CPO clones using the primers indicated in (**A**) to selectively amplify the 1.6 kb WT gene or the 1.1 kb truncated gene. (**C**) Southern blot analysis of gDNA from 3D7 WT and ∆CPO clonal parasites after digestion with XhoI and KpnI, hybridization with a CPO bp 610--1080 oligonucleotide probe, and detection using the Amersham AlkPhos Labeling and CDP-Star chemiluminescent reagents. (**D**) Homology model of *P. falciparum* CPO (human CPO template structure 2AEX) to indicate the portion of the protein retained (blue) or lost (green) by single-crossover truncation. The deleted sequence comprises half of the active site binding pocket, identified by the citrate molecule shown in red.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.016](10.7554/eLife.09143.016)10.7554/eLife.09143.017Figure 2---figure supplement 5.IFM images of fixed 3D7 parasites expressing full-length ALAD tagged at its endogenous locus with C-terminal GFP confirm targeting to the parasite apicoplast.Parasites were stained with αGFP and αACP (ACP, apicoplast marker).**DOI:** [http://dx.doi.org/10.7554/eLife.09143.017](10.7554/eLife.09143.017)10.7554/eLife.09143.018Figure 2---figure supplement 6.PCR analysis of genomic DNA from untreated WT parasites or parasites cultures ≥7 days in 1 µM doxycycline and 200 µM IPP.ACP~L~ refers to the 385 bp leader sequence (with introns) of the nuclear-encoded ACP. Rps8 (387 bp) and ORF91 (276) are two genes encoded by the Plasmodium apicoplast genome.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.018](10.7554/eLife.09143.018)10.7554/eLife.09143.019Figure 2---figure supplement 7.Western blot analysis of parasites episomally expressing ALAD-GFP and cultured 7 days in IPP and doxycycline.Blots confirm disrupted proteolytic processing of the ALAD leader sequence that results in retarded migration by SDS-PAGE relative to parasites cultured in normal conditions. Extracts from WT and IPP/doxycycline parasites were loaded separately in lanes 2 and 5, respectively, and were loaded together in lanes 3 and 4.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.019](10.7554/eLife.09143.019)

To further probe the functional contributions to heme biosynthesis by the parasite apicoplast and its constituent enzymes, we stably disrupted this organelle by treating parasites with doxycycline and isopentenyl pyrophosphate (IPP). Doxycycline inhibits the prokaryotic translation machinery of the apicoplast, which blocks replication of the small apicoplast genome, prevents organelle segregation, and results in unviable apicoplast-deficient parasite progeny ([@bib8]). The lethal effects of doxycycline, however, can be chemically rescued by IPP, which enables parasites to make essential isoprenoids despite apicoplast disruption. This rescue leads to a stable metabolic state in which parasites lack the intact organelle such that nuclear-encoded proteins ordinarily targeted to the apicoplast become stranded in small vesicles ([@bib61]). We confirmed apicoplast loss in doxycycline and IPP-treated parasites by using microscopy to verify disrupted apicoplast targeting of the nuclear-encoded ALAD enzyme ([Figure 2D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}), PCR to confirm loss of the small apicoplast genome ([Figure 2---figure supplement 6](#fig2s6){ref-type="fig"}), and western blot (WB) to visualize disruption of post-translational processing of ALAD ([Figure 2---figure supplement 7](#fig2s7){ref-type="fig"}). Despite apicoplast disruption, these parasites retained their capacity for heme biosynthesis ([Figure 2A](#fig2){ref-type="fig"}) and remained fully photosensitive in ALA ([Figure 2E](#fig2){ref-type="fig"}). Together with the gene disruption results above, these observations strongly suggested that parasite-infected erythrocytes have a parallel biosynthetic pathway that bypasses functional disruption of the parasite enzymes targeted to the apicoplast and cytoplasm.

Erythrocytes retain vestigial heme biosynthesis enzymes with latent activity stimulated by ALA {#s2-3}
----------------------------------------------------------------------------------------------

The heme biosynthesis pathway in human cells is distributed between mitochondria and the cytoplasm, with four cytosolic enzymes that correspond to the four apicoplast-targeted enzymes in *Plasmodium* parasites ([@bib38], [@bib39]; [@bib55]). During human erythropoiesis, precursor reticulocytes carry out prolific heme biosynthesis, but this activity is absent in mature erythrocytes due to loss of mitochondria and their constituent heme biosynthesis enzymes, including ALAS and FC ([@bib38]). Proteomic studies have confirmed that mature erythrocytes retain the cytosolic enzymes (ALAD, PBGD, uroporphyrinogen synthase \[UROS\], and uroporphyrinogen decarboxylase \[UROD\]) ([@bib37]; [@bib10]), but this vestigial pathway is ordinarily quiescent due to the lack of ALA synthesis or uptake in erythrocytes. We hypothesized that exogenous ALA taken up by parasite-infected erythrocytes might stimulate the latent activity of these cytosolic human enzymes, resulting in biosynthetic flux through this truncated host pathway and production of downstream tetrapyrrole intermediates that could be taken up by the parasite via hemoglobin import or other mechanisms and converted into heme within the parasite mitochondrion.

The cytosolic human enzymes remaining in the mature erythrocyte would be expected to produce CPP from ALA. Our observation that disruption of the parasite CPO had no effect on conversion of ALA into heme by intraerythrocytic parasites suggests that a soluble fraction of human CPO, which is thought to be predominantly targeted to the mitochondrial intermembrane space (IMS) ([@bib38]; [@bib55]), persists in the erythrocyte cytoplasm after maturation of precursor reticulocytes and mitochondrial loss. Indeed, other mitochondrial IMS proteins, such as cytochrome c, are known to partition into the cytoplasm under certain conditions ([@bib27]; [@bib47]). CPO catalyzes production of protoporphyrinogen IX, which in the oxygen-rich environment of erythrocytes can spontaneously oxidize to form PPIX ([@bib58]).

In support of this model, we noted that red porphyrin fluorescence in ALA-treated infected erythrocytes was not limited to the parasite but was detectable throughout the erythrocyte cytoplasm ([Figure 1B](#fig1){ref-type="fig"}), as expected for host enzyme activity and production of PPIX in this compartment. To directly test the model that enzymes remaining in the erythrocyte cytoplasm could catalyze PPIX biosynthesis from ALA, we permeabilized uninfected erythrocytes using the detergent saponin, clarified lysates by centrifugation followed by sterile filtration, and then used LC-MS/MS to monitor heme and porphyrin biosynthesis from 5-\[^13^C~4~\]-ALA added to the filtered lysate supernatant. We detected formation of ^13^C-labelled PPIX and CPP but not heme, and this biosynthetic activity was fully blocked by SA ([Figure 3A](#fig3){ref-type="fig"}). These observations provide direct support for our model that erythrocytes retain a vestigial and partial biosynthesis pathway capable of converting exogenous ALA into PPIX but are unable to convert PPIX to heme due to lack of mitochondria and FC.10.7554/eLife.09143.020Figure 3.Erythrocytes have latent porphyrin biosynthesis activity that requires exogenous ALA and parasite permeability mechanisms to enable ALA uptake.(**A**) LC-MS/MS detection of ^13^C-labelled PPIX and CPP in erythrocyte lysate supernatants incubated with 200 µM 5-\[^13^C~4~\]-ALA without or with 50 µM SA. Erythrocytes were lysed in 0.04% saponin, centrifuged at 25,000×*g* for 60 min, and 0.2 µM syringe filtered prior to ALA addition. (**B**) Bright field and fluorescence (Zeiss filter set 43 HE) images of uninfected erythrocytes incubated in 500 µM ALA before or after electroporation. (**C**) Bright-field and fluorescence images of parasites cultured in 500 µM ALA with normal (+TMP) or blocked (−TMP) establishment of parasite permeability pathways in the erythrocyte membrane. Infected erythrocyte permeability was modulated using a 3D7 parasite line expressing HSP101 tagged at its endogenous locus with a TMP-dependent destabilization domain ([@bib3]). TMP was maintained or washed out from synchronous schizont-stage parasites, which were allowed to rupture and invade new erythrocytes. 500 µM ALA was added to both cultures after invasion, and parasites were imaged 8 hr later.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.020](10.7554/eLife.09143.020)10.7554/eLife.09143.021Figure 3---figure supplement 1.Furosemide blocks ALA uptake and PPIX biosynthesis in parasite-infected erythrocytes.Asynchronous wild-type 3D7 parasites were incubated in the absence or presence of 100 µM furosemide for 1 hr to block nutrient acquisition pathways, followed by addition of 500 µM ALA and further incubation for 8 hr. Parasites were then imaged by live microscopy on the bright field or red fluorescence (Zeiss filter set 43 HE) channels. In lower panel, parasite nuclei (blue) were visualized with Hoechst DNA stain.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.021](10.7554/eLife.09143.021)

ALA uptake by erythrocytes requires new permeability pathways established by *Plasmodium* infection {#s2-4}
---------------------------------------------------------------------------------------------------

In contrast to parasite-infected erythrocytes, uninfected erythrocytes showed no detectable porphyrin fluorescence in the presence of ALA ([Figure 3B](#fig3){ref-type="fig"}), consistent with reports that the erythrocyte membrane has a low permeability to amino acids ([@bib16]; [@bib23]; [@bib12]). Electroporation of uninfected erythrocytes in the presence of ALA, however, resulted in robust intracellular porphyrin fluorescence ([Figure 3B](#fig3){ref-type="fig"}), supporting our model that host enzymes have latent biosynthetic activity that requires a mechanism for ALA uptake across the normally impermeable erythrocyte membrane.

Upon invasion, *Plasmodium* parasites export hundreds of effector proteins into host erythrocytes. These proteins dramatically alter the architecture of the infected erythrocyte and establish new permeability pathways (NPPs) that enhance host cell uptake of amino acids and other nutrients from host serum ([@bib48]). We hypothesized that selective uptake of ALA by parasite-infected erythrocytes was mediated by NPP mechanisms.

To test this model, we utilized a recently published parasite line in which the export of parasite proteins into host erythrocytes, including establishment of nutrient permeability pathways, can be conditionally regulated with the synthetic small-molecule ligand trimethoprim (TMP) ([@bib3]). In these parasites, protein export and NPP mechanisms are functional in the presence of TMP but are blocked in its absence. We maintained or washed out TMP from a synchronized culture of late schizonts, allowed parasites to rupture and reinvade new erythrocytes, and then incubated both sets of parasites in ALA for 8 hr. Whereas TMP-treated parasites with normal protein export and permeability displayed robust PPIX fluorescence indistinguishable from that of wild-type parasites, parasites incubated without TMP showed no detectable PPIX fluorescence ([Figure 3C](#fig3){ref-type="fig"}). We observed similar results in wild-type parasites using the small-molecule drug furosemide, which blocks parasite-derived NPP mechanisms directly ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) ([@bib49]). We conclude that ALA is selectively taken up by infected erythrocytes via parasite-dependent nutrient-acquisition pathways and metabolized to PPIX by vestigial host enzymes within the erythrocyte cytoplasm ([Figure 4](#fig4){ref-type="fig"}).10.7554/eLife.09143.022Figure 4.Schematic depiction of ALA-uptake and porphyrin biosynthesis pathways in Plasmodium-infected erythrocytes.For simplicity, all membranes are depicted as single. Porphyrins synthesized in the infected erythrocyte cytoplasm from exogenous ALA may be transported across the parasite membrane via unspecified mechanisms or may be taken up via hemoglobin import mechanisms. SA inhibits ALAD and blocks porphyrin synthesis from ALA.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.022](10.7554/eLife.09143.022)10.7554/eLife.09143.023Figure 4---figure supplement 1.Growth of parasites in 1 µM 5-\[^13^C~4~\]-ALA results in detectable biosynthesis of ^13^C-labeled PPIX.Parasites were grown overnight in 1 µM 5-\[^13^C~4~\]-ALA, permeabilized with saponin, extracted in DMSO, and analyzed by LC-MS/MS for ^13^C-labeled heme, PPIX, and CPP. Integrated peak areas measured for each analyze were normalized to that measured for the deuteroporphyrin internal standard added to each sample.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.023](10.7554/eLife.09143.023)

The *Plasmodium*-encoded heme biosynthesis pathway has no detectable activity during blood-stage infection {#s2-5}
----------------------------------------------------------------------------------------------------------

Our observation that disruption of the parasite-encoded PBGD and CPO does not affect biosynthetic production of heme and PPIX from ALA suggests that host enzyme activity in the erythrocyte cytoplasm provides the dominant contribution to PPIX biosynthesis in ALA-treated intraerythrocytic parasites. To dissect these parallel pathways and test whether the parasite pathway alone, in the absence of host enzymes, can support heme biosynthesis from ALA, we fractionated parasite-infected erythrocytes using saponin to selectively permeabilize host cell membranes while leaving parasite membranes intact ([Figure 5A](#fig5){ref-type="fig"}). Under these conditions, soluble erythrocyte proteins can be washed away to leave the intact live parasite natively embedded within the resulting erythrocyte ghost ([Figure 5B,C](#fig5){ref-type="fig"}). Parasites treated in this fashion remain metabolically active for 5--6 hr or longer, retain a membrane potential, accumulate fluorescent dyes such as MitoTracker Red ([Figure 5B,C](#fig5){ref-type="fig"}), and carry out DNA synthesis ([@bib19]; [@bib7]). After saponin treatment and washout, we placed parasites back into culture medium containing ^13^C-ALA and incubated them overnight before extracting them for analysis by LC-MS/MS. We failed to detect biosynthesis of heme, PPIX, or CPP in fractionated asexual and sexual blood-stage parasites ([Figure 5D](#fig5){ref-type="fig"}), suggesting that the apicoplast-localized portion of the parasite heme biosynthesis pathway is largely or completely inactive during blood-stage infection.10.7554/eLife.09143.024Figure 5.Analysis of heme biosynthesis activity in parasite-infected erythrocytes after saponin permeabilization and culture in ^13^C-labelled ALA.(**A**) Parasite-infected erythrocytes were permeabilized in 0.02% saponin, washed to remove the erythrocyte cytoplasm, and placed back into culture medium containing 200 µM 5-\[^13^C~4~\]-ALA for 12 hr prior to DMSO extraction and analysis by LC-MS/MS. Bright field and fluorescence image of live (**B**) asexual trophozoite and (**C**) stage IV sexual gametocyte treated with 0.02% saponin and stained with 20 nM MitoTracker Red. (**D**) LC-MS/MS quantification of ^13^C-labelled heme, PPIX, and CPP in DMSO extracts of intact WT 3D7 asexual parasites, saponin-released asexual parasites, and saponin-released gametocytes cultured overnight in 200 µM 5-\[^13^C~4~\]-ALA.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.024](10.7554/eLife.09143.024)

To test this conclusion within undisrupted parasites, we created a transgenic parasite line expressing an apicoplast-targeted version of the uroporphyrinogen III methyltransferase (cobA) protein from *Propionibacterium freudenreichii* to serve as a biosensor of heme biosynthesis pathway activity within the parasite apicoplast. The cobA protein catalyzes conversion of the heme biosynthesis intermediate uroporphyrinogen III into the red fluorescent products sirohydrochlorin and trimethylpyrrocorphin ([Figure 6A](#fig6){ref-type="fig"}) and has been shown to function when heterologously expressed in bacteria ([Figure 6B](#fig6){ref-type="fig"}), yeast, and mammalian cells ([@bib42]; [@bib60]). We targeted a cobA-green fluorescent protein (GFP) fusion protein to the apicoplast in ALA-treated parasites ([Figure 6C](#fig6){ref-type="fig"}) but were unable to detect any red fluorescence in this organelle indicative of cobA-mediated conversion of uroporphyrinogen III to the fluorescent products. This result suggests that parasite enzymes targeted to this organelle are inactive in both asexual and sexual blood stages ([Figure 6D,E](#fig6){ref-type="fig"}). We also noted that growth of ∆FC parasites ([@bib21]), which would be expected to accumulate PPIX during native pathway activity ([Figure 1A](#fig1){ref-type="fig"}), was insensitive to light in the absence of ALA ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). These observations suggest that heme biosynthesis in blood-stage *P. falciparum* parasites is only operative when exogenous ALA is present to stimulate PPIX production by remnant host enzymes in the erythrocyte cytoplasm, with subsequent PPIX uptake and conversion to heme by FC in the parasite mitochondrion ([Figure 4](#fig4){ref-type="fig"}).10.7554/eLife.09143.025Figure 6.Analysis of heme biosynthetic flux within the apicoplast of live parasites using the cobA biosensor.(**A**) Fluorescence excitation (black) and emission (red) spectra of clarified lysates from *Escherichia coli* bacteria expressing the cobA gene from *Propionibacterium freudenreichii* (*shermanii*), showing the expected peaks for conversion of uroporphyrinogen III to sirohydrochlorin and trimethylpyrrocorphin. (**B**) Fluorescence microscopy images of live bacteria expressing the cobA gene, acquired on the bright field and red (Zeiss filter set 43 HE) channels. (**C**) Immunofluorescence (IFM) images of fixed 3D7 parasites episomally expressing an ACP~leader~-cobA-GFP fusion confirm targeting to the parasite apicoplast. Parasites were stained with αGFP and αACP (acyl carrier protein \[ACP\], apicoplast marker). The αACP antibody recognizes an epitope that is different from the ACP leader sequence. (**D**) Fluorescence microscopy images of live asexual parasites episomally expressing ACP~leader~-cobA-GFP without or with 500 µM exogenous ALA. (**E**) Fluorescence microscopy images of live stage III--IV sexual gametocytes episomally expressing ACP~leader~-cobA-GFP without or with 500 µM exogenous ALA. Fluorescence images in (**D**) and (**E**) were acquired on the GFP (Zeiss filter set 38) and red (Zeiss filter set 43 HE) channels.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.025](10.7554/eLife.09143.025)10.7554/eLife.09143.026Figure 6---figure supplement 1.Disruption of the *Plasmodium* FC gene in ∆FC parasites does not photosensitize parasites.WT or ∆FC D10 parasites were cultured under normal growth conditions (without exogenous ALA) with 2-min light exposures on an overhead projector light box on days 0--2. Culture parasitemia as a function of time was fit to an exponential growth model. Both WT and ∆FC parasites had parasitemia doubling times of 1.1 days under these conditions.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.026](10.7554/eLife.09143.026)

Development of chemiluminescence-based PDT for treatment of blood-stage malaria {#s2-6}
-------------------------------------------------------------------------------

Our results and those of prior studies suggested that stimulation of heme biosynthesis might be exploited for antimalarial PDT. Conventional PDT requires an external light source to photoactivate and kill ALA-stimulated cells ([@bib20]; [@bib5]; [@bib56]). While such approaches can successfully target localized shallow-tissue tumors ([@bib5]; [@bib56]), they are impractical for treating malaria due to the dispersed nature of blood-stage infection, the sequestration of mature *P. falciparum* parasites along the vascular endothelium, and the requirement to illuminate every infected erythrocyte.

To bypass the need for external light, chemiluminescence has been proposed as an alternative means to photoactivate the cytotoxicity of PPIX in ALA-stimulated cells. Trial studies in cancer cell lines have shown modest success using the small molecule luminol ([@bib25]; [@bib6]), whose iron-activated chemiluminescence ([@bib41]) overlaps the absorbance spectrum of PPIX ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Cancer cells tightly sequester iron, which may limit luminol activation in these environments. *Plasmodium* parasites, however, expose abundant iron during large-scale digestion of erythrocyte hemoglobin and liberation of heme. We therefore hypothesized that intraerythrocytic parasites might show heightened susceptibility to chemiluminescence-based PDT (CL-PDT) ([Figure 7A](#fig7){ref-type="fig"}).10.7554/eLife.09143.027Figure 7.Targeting blood-stage Plasmodium parasites by chemiluminescence-based photodynamic therapy (CL-PDT).(**A**) Schematic depiction of a CL-PDT mechanism for targeting blood-stage malaria. (**B**) Effect of 100 µM ALA, 750 µM luminol (lum), 50 µM 4-iodophenol (ph), 50 µM SA and their combination (all 0.25% DMSO) on the growth of asynchronous 3D7 parasites. (**C**) Effect of 100 µM ALA, 750 µM luminol, 0.5 nM dihydroartemisinin (DHA), 50 µM SA and their combination (all 0.25% DMSO) on the growth of asynchronous 3D7 parasites. Parasite media was changed twice daily, and parasitemia increases were fit to an exponential growth equation.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.027](10.7554/eLife.09143.027)10.7554/eLife.09143.028Figure 7---figure supplement 1.Spectral compatibility of luminol and PPIX.(**A**) Overlay of normalized absorbance spectrum of PPIX (black) and chemiluminescence spectrum of luminol (red). (**B**) Chemiluminescence of luminol (solid red) is attenuated in the presence of PPIX (solid black), giving rise to a difference spectrum (dashed black) that is similar to the absorbance spectrum of PPIX in the spectral region that overlaps luminol chemiluminescence. Solutions contained 25 mM luminol in 100 mM NaOH (aq), 0.5% (wt/vol) ammonium persulfate, and/or 70 µM PPIX.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.028](10.7554/eLife.09143.028)10.7554/eLife.09143.029Figure 7---figure supplement 2.Effect of combinatorial ALA, luminol, and 4-iodophenol treatment on parasite growth.(**A**) Luminol concentrations as high as 750 µM (in 0.2% DMSO) have no effect on 3D7 parasite growth over 48 hr. (**B**) Effect of 750 µM luminol, 100 µM ALA, and their combination (all in 0.2% DMSO) on the growth of asynchronous 3D7 parasites. (**C**) Concentration dependence of growth inhibition of 3D7 parasites by 4-iodophenol (in 0.2% DMSO) over 48 hr. (**D**) Effect of 100 µM ALA, 50 µM 4-iodophenol, and their combination (all in 0.2% DMSO) on the growth of asynchronous 3D7 parasites.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.029](10.7554/eLife.09143.029)10.7554/eLife.09143.030Figure 7---figure supplement 3.Giemsa-stained blood smear of 3D7 parasite culture after 3 days of treatment in 100 µM ALA, 750 µM luminol, and 50 µM 4-iodophenol.Arrows point to dead parasite remnants.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.030](10.7554/eLife.09143.030)10.7554/eLife.09143.031Figure 7---figure supplement 4.Efficacy of CL-PDT with drug-resistant parasites.Effect of 100 µM ALA, 750 µM luminol, 50 µM 4-iodophenol, 50 µM SA (all 0.2% DMSO) and their combination on the growth of asynchronous (**A**) Dd2 parasites or (**B**) Kelch-13 I543T (MRA-1241) parasites.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.031](10.7554/eLife.09143.031)10.7554/eLife.09143.032Figure 7---figure supplement 5.Concentration dependence of growth inhibition of 3D7 parasites by DHA over 48 hr (in 0.2% DMSO).**DOI:** [http://dx.doi.org/10.7554/eLife.09143.032](10.7554/eLife.09143.032)10.7554/eLife.09143.033Figure 7---figure supplement 6.Effect of 500 pM DHA, 100 µM ALA, and their combination (all in 0.2% DMSO) on the growth of asynchronous 3D7 parasites.**DOI:** [http://dx.doi.org/10.7554/eLife.09143.033](10.7554/eLife.09143.033)

To test the efficacy of a CL-PDT strategy for targeting blood-stage *P. falciparum*, we incubated intraerythrocytic parasites with twice-daily media changes in combinatorial treatments of ALA, luminol, and 4-iodophenol, a small molecule that has been shown to enhance the intensity and duration of luminol chemiluminescence ([@bib53]). Parasites treated with optimized concentrations of each compound in single or double combination showed little effect on parasite growth ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). The combination of all three compounds, however, potently inhibited parasite growth ([Figure 7B](#fig7){ref-type="fig"}), and microscopic examination by blood smear revealed widespread parasite death ([Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}). The growth effects of this combination could be fully rescued by SA ([Figure 7B](#fig7){ref-type="fig"}), supporting a photodynamic mechanism requiring PPIX biosynthesis from ALA and enhanced chemiluminescence by luminol.

The development of parasite resistance to frontline antimalarial drugs continues to hamper malaria treatment and eradication efforts worldwide. To test whether a CL-PDT mechanism remains effective against parasites with diverse resistance to distinct drugs, we turned to studies with Dd2 parasites, which have multidrug resistance to antifolate and quinolone antibiotics ([@bib43]), and a clinical isolate containing a kelch-13 protein mutation that confers artemisinin tolerance ([@bib1]). In both parasite lines, combination treatment with ALA, luminol, and 4-iodophenol potently ablated parasite growth ([Figure 7---figure supplement 4](#fig7s4){ref-type="fig"}).

Artemisinin and its derivatives are current frontline drugs used for treatment of malaria, usually in combination with a partner drug. Artemisinin, whose endoperoxide moiety is reductively cleaved by intracellular iron to generate reactive oxygen radicals ([@bib30]), has been shown to potently stimulate luminol chemiluminescence in vitro ([@bib18]), suggesting the possibility of combining CL-PDT with artemisinin for antimalarial treatment. To test the efficacy of an artemisinin-enhanced CL-PDT strategy, we incubated drug-sensitive 3D7 parasites with twice-daily media changes in ALA, luminol, and sub-therapeutic doses (500 pM, 10% of EC~50~, [Figure 7---figure supplement 5](#fig7s5){ref-type="fig"}) of dihydroartemisinin (DHA). Single and double combinations had little effect ([Figure 7---figure supplement 6](#fig7s6){ref-type="fig"}), but all three compounds together potently ablated parasite growth, and growth inhibition could be fully rescued with SA ([Figure 7C](#fig7){ref-type="fig"}).

Discussion {#s3}
==========

Malaria parasites, like nearly all other organisms, have a metabolic requirement for heme ([@bib35]; [@bib55]; [@bib44]). Despite access to abundant host heme during intraerythrocytic infection, parasites retain a complete heme biosynthesis pathway that was regarded for two decades as essential and a potential drug target ([@bib52]). Our work and recent studies have now successfully disrupted four of the eight pathway enzymes, providing firm evidence that de novo heme synthesis is dispensable during blood-stage infection. These data strongly suggest that parasites have mechanisms to scavenge host heme to meet metabolic needs and clarify that heme biosynthesis is not a viable target for classical drug inhibition ([@bib32]; [@bib21]).

Our results further suggest that the parasite pathway is not active during intraerythrocytic infection. This inactivity may reflect the low availability of the succinyl-CoA precursor due to limited tricarboxylic acid cycle flux ([@bib29]) and additional regulatory mechanisms that suppress the activity of apicoplast-targeted enzymes during blood-stage parasite development, such as feedback inhibition by host heme or active-site inhibition by endogenous metabolites ([@bib36]),. The functional quiescence of this specific biosynthetic pathway, despite expression of the constituent enzymes, may reflect a general survival strategy and adaptation by parasites to closely match their metabolic requirements with the nutritional availability of specific host environments, such as those previously described for parasite acquisition of fatty acids ([@bib62]). Indeed, prior studies suggest that the parasite heme synthesis pathway is required for development within the mosquito and human liver ([@bib32]; [@bib21]). These stages involve host environments with lower heme availability compared with erythrocytes and in which parasite heme requirements appear to be elevated due to enhanced reliance on mitochondrial electron transport for ATP synthesis ([@bib55]; [@bib44]; [@bib51]). A prior study reported that blood-stage *P. falciparum* parasites adopt distinct physiological states in vivo, including a state with heightened oxidative metabolism and mitochondrial activity that may arise during host starvation ([@bib9]). It remains a future challenge to test whether heme biosynthesis by the parasite-encoded pathway can be stimulated by host nutritional status during intraerythrocytic infection.

Despite the dispensable nature and apparent inactivity of the parasite-encoded heme biosynthesis pathway, infected erythrocytes retain a paradoxical ability to synthesize heme from exogenous ALA. This biosynthetic activity requires the *Plasmodium* FC but not the upstream enzymes in the parasite pathway. Indeed, knock-out of the *Plasmodium* FC prevented conversion of PPIX to heme ([@bib21]), but our disruption of the parasite PBGD and CPO genes, as well as the entire apicoplast organelle, had no effect on ALA-stimulated heme synthesis ([Figure 2](#fig2){ref-type="fig"}). Our work resolves this paradox by identifying a latent contribution to heme biosynthesis in parasite-infected erythrocytes from vestigial host enzymes remaining in the erythrocyte cytoplasm. Since erythrocytes lack mitochondria, they are missing the initial and terminal pathway enzymes, are unable to synthesize ALA, and thus retain only a truncated and normally inactive heme synthesis pathway. Analytical studies have reported that human serum contains 0.1--0.2 µM ALA ([@bib63]), but the low permeability of the erythrocyte membrane to ALA means that extracellular ALA is largely inaccessible to vestigial host enzymes within uninfected erythrocytes.

Our study clarifies that NPP mechanisms of parasite-infected red blood cells enable efficient uptake of exogenous ALA. After uptake, ALA can be metabolized by vestigial human enzymes within the oxygen-rich erythrocyte cytoplasm to produce PPIX that can be converted to heme by FC within the parasite mitochondrion ([Figure 4](#fig4){ref-type="fig"}). Thus, the 0.2 µM ALA natively present in human serum may be sufficient to stimulate low-level heme biosynthesis within parasites in vivo. Indeed, we detect ^13^C-labeled PPIX in parasites grown in 1 µM 5-\[^13^C~4~\]-ALA in vitro ([Figure 4---figure supplementary 1](#fig4s1){ref-type="fig"}), supporting a model that serum ALA stimulates heme biosynthesis during malaria infection in vivo. Such activity, however, is not required to support blood-stage parasite growth. We note that prior work suggested a role for remnant host enzymes in heme biosynthesis by malaria parasites, but this prior proposal differed by positing that human enzymes such as ALAD were somehow imported and active within the parasite cytoplasm ([@bib34]).

The ability to photosensitize parasites with exogenous ALA and then kill them with light introduces exciting possibilities for developing new photodynamic treatment strategies, exemplifies how a deep understanding of fundamental parasite metabolism can be leveraged for designing novel therapies, and highlights that non-essential pathways can still serve as therapeutic targets. We have shown that luminol-based chemiluminescence, when stimulated by combinatorial delivery of low-dose 4-iodophenol or artemisinin, can circumvent the conventional PDT requirement for external light and potently ablate parasite growth ([Figure 7](#fig7){ref-type="fig"}). We note that ALA, luminol, and DHA have excellent toxicity profiles, favorable pharmacokinetic properties, and have each been used clinically ([@bib4]; [@bib11]; [@bib17]; [@bib26]; [@bib56]). These results suggest the possibility of including ALA and luminol with therapeutic doses of artemisinin (or its clinical derivatives) as a novel form of artemisinin combination therapy for treating malaria. Multidrug-resistant parasites remain susceptible to this photodynamic strategy, which relies on host enzyme activity outside the genetic control of parasites and thus is refractory to the development of resistance-conferring mutations. This CL-PDT strategy may also be effective against other intraerythrocytic parasites, such as *Babesia*. As for any new therapy suggested by in vitro studies, additional in vivo experiments will be required to optimize treatment regimens for our proposed therapy and to confirm efficacy and safety.

Finally, we note that this strategy of using artemisinin to stimulate intracellular light emission by luminol for ALA-based PDT may be applicable to treating deep-tissue cancers, for which poor accessibility to external light also limits current PDT approaches in development for cancer therapy ([@bib5]). Artemisinin has shown promising anti-cancer properties on its own ([@bib33]), and thus its combination with ALA and luminol may provide potent synergy for cancer chemotherapy.

Materials and methods {#s4}
=====================

Materials {#s4-1}
---------

All reagents were of the highest purity commercially available. SA, 5-ALA, 4-iodophenol, TMP, furosemide, saponin, IPP, doxycycline, luminol, and DHA were purchased from Sigma (St. Louis, MO, USA). 5-\[^13^C~4~\]-ALA was purchased from Cambridge Isotope Laboratories, Inc (Tewksbury, MA, USA).

Microscopy {#s4-2}
----------

Images of live or fixed parasites were acquired on an Axio Imager M1 epifluorescence microscope (Carl Zeiss Microimaging, Inc.) equipped with a Hamamatsu ORCA-ER digital CCD camera and running Axiovision 4.8 software, as described previously ([@bib45]). Live parasite nuclei were stained with 5 µM Hoechst 3342 added immediately prior to image acquisition. For photodynamic imaging studies, parasites were cultured in 200--500 µM ALA in the absence or presence of 50 µM SA for 6--12 hr prior to visualization. Hemozoin movement in parasite digestive vacuoles was imaged by acquiring 10--20 sequential frames at 1 s intervals on the bright-field channel. Images were cropped and superimposed in Adobe Photoshop, exported as video files with a 0.1 s frame delay, and looped for 15 seconds of playback. Immunofluorescence (IFM) images were acquired by fixing and staining parasites as previously described ([@bib54]; [@bib40]). Electron microscopy images of parasites subjected to light or 500 µM ALA + light were obtained as previously described ([@bib3]). Uninfected erythrocytes were washed and resuspended in 1× cytomix containing 500 µM ALA, electroporated in a manner identical to parasite transfections (see below), washed in phosphate-buffered saline (PBS), incubated overnight at 37°C, and imaged as described above for live parasites. Images acquired on different channels for common samples were processed with identical brightness and contrast settings.

Parasite growth analysis {#s4-3}
------------------------

Parasite growth was monitored by diluting asynchronous parasites to 0.5% parasitemia and allowing culture expansion with daily or twice-daily media changes. Parasitemia was measured daily by diluting 10 µl of each resuspended culture in 200 µl acridine orange (1.5 µg/ml) and analyzing by flow cytometry, as previously described ([@bib31]). To assess the light sensitivity of ALA-treated parasites, asynchronous parasites were cultured in 200 µM ALA in the absence or presence of 50 µM SA and subjected to 2 min daily exposures to broad-wavelength white light on an overhead projector. Daily parasitemia measurements were plotted as a function of time and fit to an exponential growth equation using GraphPad Prism 5.0.

For chemiluminescence experiments, asynchronous parasites were diluted to 0.5% parasitemia and incubated in ±100 µM ALA and ±50 µM SA for 8 hr. After 8 hr, parasite media was changed to also include 750 µM luminol, 50 µM 4-iodophenol, and 0.5 nM DHA in the indicated combinations. Parasite cultures were allowed to expand over 5 days, with twice-daily (7 am and 4 pm) media changes in the indicated combinations. Parasitemia was measured daily on replicate samples, as indicated above. Experiments were performed using 3D7 (drug sensitive) parasites, Dd2 (multidrug resistant) parasites ([@bib43]), and a clinical isolate ([@bib1]) (MRA-1241) bearing the I543T mutation in the Kelch-13 gene locus responsible for artemisinin tolerance. Exposure of parasite cultures to ambient light was minimized by changing media within darkened TC hoods and covering parasite culture dishes during brief (5--10 s) transits to and from incubators. The effect of 100 µM ALA on parasite growth varied slightly between experiments, possibly due to differences between distinct batches of donated erythrocytes.

For IC~50~ determinations, asynchronous parasites were diluted to 1% parasitemia and incubated with variable drug concentrations for 48 hr without media change. After 48 hr, parasitemia was determined in duplicate samples for each drug concentration, normalized to the parasitemia in the absence of drug, plotted as a function of the log of the drug concentration, and fit to a sigmoidal growth inhibition curve using GraphPad Prism 5.0.

Parasite strains, culture, genetic modification, and transgene expression {#s4-4}
-------------------------------------------------------------------------

Parasite culture and transfection were performed in Roswell Park Memorial Institute medium (RPMI) supplemented with Albumax, as previously described ([@bib45]). Cloning was performed using either restriction endonuclease digestion and ligation or the In-Fusion system (Clontech Mountain View, CA, USA).

For episomal expression of *P. falciparum* ALA dehydratase (PF3D7_1440300) and CPO (PF3D7_1142400) fused to a C-terminal GFP tag (ALAD-GFP and CPO-GFP), cDNA inserts encoding the complete ALAD and CPO genes (exons only) were reverse transcription (RT)-PCR amplified from total parasite RNA using the Superscript III system (Life Technologies) and primers CACTATAGAACTCGAGATGTTAAAATCAGATGTA GTGCTTTTATTGTATATAC and CTGCACCTGGCCTAGGTAGAGTTAATTCTATATT AAAATTATTATTTGAATTATCATC (ALAD) or ACGATTTTTTCTCGAGATGAAA GATGAGATAGCTCCTAATGAATATTTTAGAAATTTATG and CTGCACCTGGCCT AGGGTAGTCCACCCACTTTTTGGGATAC (CPO). These were digested with XhoI/AvrII and ligated into the XhoI/AvrII sites of a digested pTEOE vector that was identical to a previously described pTyEOE vector ([@bib3]) except that the pTEOE plasmid contained human dihydrofolate reductase (DHFR) in place of yeast dihydroorotate dehydrogenase (yDHOD) as the positive selection marker. Plasmid-based expression of the ALAD−GFP fusion was driven by the HSP86 promoter. This plasmid (50 µg) was co-transfected into 3D7 parasites along with plasmid pHTH (10 µg) for transient expression of the *piggyback* transposase that mediates integration of the pTEOE plasmid into the parasite genome ([@bib2]). Parasites were selected with 5 nM WR99210.

For episomal expression of *P. freudenreichii* (*shermanii*) uroporphyrinogen III methyltransferase (cobA) (Genbank: CBL55989.1) targeted to the parasite apicoplast, the cobA gene was PCR amplified from plasmid pISA417 ([@bib42]) using the primers ACGATTTTTTCTCGAGATGACCACCACACTGTTGCCCGGCACTGTC and CTGCACCT GGCCTAGGGTGGTCGCTGGGCGCGCGATGG, digested with XhoI/AvrII and ligated into the XhoI/AvrII-cut pTEOE vector described above. An insert encoding the *P. falciparum* acyl carrier protein (ACP) leader sequence (residues 1--60) with 5′- and 3′-XhoI sites, previously PCR amplified from parasite cDNA ([@bib45]), was digested with XhoI and ligated into the XhoI-cut cobA/pTEOE vector to generate an in-frame ACP~L~-cobA-GFP fusion gene. This plasmid was co-transfected with pHTH into 3D7 parasites as described above.

For disruption of the *P. falciparum* genes encoding PBGD (PF3D7_1209600) and CPO (PF3D7_1142400), primer pairs (PBGD: CACTATAGAACTCGAGGATCATAATAA TGATACATTATGTACTATTGGGACATCGTCC and CTGCACCTGGCCTAGGAA CTGCTATAATGCCTTGACCTAAGGCAGGATAAATCAGG; CPO: CACTATAG AACTCGAGTTTTTTCAAATATTTATAAAAACAGGAAAAAAGAAGAAAAAATA and CTGCACCTGGCCTAGGATAACATTTACAATCCTTATTATTATTATTATTATTGTTG ATGG) were used to PCR amplify 360 bp and 471 bp sequences from the middle of the 1.3 kb PBGD and 1.6 kb CPO genes, respectively. These inserts were cloned by In-Fusion into the XhoI/AvrII sites of the pPM2GT vector ([@bib24]), which encodes a C-terminal GFP tag after the AvrII site and also contains a human DHFR marker for positive selection with 5 nM WR99210. This vector was further modified to introduce a 2A peptide sequence ([@bib50]) followed by the yeast DHOD sequence ([@bib14]), after the 3′ end of the GFP cassette, to enable positive selection for integration with the parasite DHOD inhibitor DSM1. The yDHOD marker, however, was not used for selection in this study, and use of the GFP-2A-yDHOD/PM2GT vector for positive selection of plasmid integration into the genome will be described elsewhere. Plasmids (50 µg) were transfected into 3D7 parasites by electroporation. Parasites were subjected to three rounds of positive selection with 5 nM WR99210. After the first and second selections, cultures were maintained for 3 weeks in the absence of drug pressure prior to the subsequent round of positive selection. After the third round of positive selection, parasites were cloned by limiting dilution. Clonal parasites that had integrated the plasmid at the desired locus to disrupt the target genes by single cross-over homologous recombination were verified by PCR and Southern blot, as previously described ([@bib24]), and retained for further analysis.

To introduce a C-terminal GFP tag into the endogenous locus of the *P. falciparum* PBGD gene (PF3D7_1209600), primer pairs CACTATAGAACTCGAGGATCATAATAA TGATACATTATGTACTATTGGGACATCGTCC and CTGCACCTGGCCTAGGTTTATTA TTTAAAAGGTGCAATTCAGCCTCCGCTTTTATTTTG were used to PCR amplify the complete PBGD coding sequence. This insert was cloned by In-Fusion into the 2A-yDHOD/PM2GT vector described above and transfected into 3D7 parasites by electroporation as above. Stable integration was achieved after three rounds of positive selection in WR99210, and clones were isolated by limiting dilution and verified by PCR and Southern blot.

∆FC D10 parasites, described in a prior study ([@bib21]), were obtained from Akhil Vaidya (Drexel University) and were cultured as described above, including 2-min daily exposures to broad-wavelength white light using an overhead projector light box.

For apicoplast disruption experiments, parasites were cultured in 1 µM doxycycline and 200 µM IPP for 7--21 days ([@bib61]). After 7 days, genomic DNA was harvested and analyzed by PCR for the nuclear-encoded ACP gene (primers ATGAAGATCTTATTACTTTGTATAATTTTTC and TTTTAAAGAGCTAGATGGGTTTTT ATTTTTTATC) and apicoplast-encoded rps8 (primers ATGATTATTAAATTTTTAAATAATG and TTACAAAATATAAAATAATAAAATACC) and ORF91 (primers ATGACTTT ATATTTAAATAAAAATTT and TTACATATTTTTTTTATTGAAGAACG) genes to confirm selective loss of the apicoplast genome.

Gametocyte induction and culturing {#s4-5}
----------------------------------

3D7 ∆PM1 (plasmepsin 1) parasites ([@bib28]) and 3D7 parasites expressing ACP~leader~-cobA-GFP from a pTEOE plasmid (described above) were synchronized using 5% sorbitol and cultured using gentamycin-free media. Gametocytogenesis was stress-induced in mid-trophozoite parasites (5--7% parasitemia) by increasing hematocrit to 4% (by removing half of the culture medium volume) for 12 hr. Parasites were maintained in culture for 4--6 days, at which point mostly stage III--IV gametocytes were visible. ACP~leader~-cobA-GFP gametocytes were incubated overnight in the presence or absence of 500 µM ALA and imaged by live parasite microscopy as described above. For ^13^C-ALA labeling experiments, gametocytes were passaged over a magnetic column to remove uninfected erythrocytes and concentrate the gametocyte-infected cells, lysed in 0.02% saponin (0.2-µM filtered), placed back into culture medium containing 200 µM 5-\[^13^C~4~\]-ALA, and incubated overnight at 37°C. Parasites were then isolated by centrifugation, extracted, and analyzed by tandem mass spectroscopy as described below.

Analysis of heme biosynthesis by ^13^C-labeling and LC-MS/MS {#s4-6}
------------------------------------------------------------

Parasites were cultured in 200 µM 5-\[^13^C~4~\]-ALA for 12--24 hr, harvested by centrifugation, lysed in 0.05% cold saponin, washed in PBS, and extracted with dimethyl sulfoxide (DMSO). Deuteroporphyrin was added as an internal standard and extracts were analyzed for ^13^C-labeled heme, PPIX, and coproporphyrin III (CPPIII) using a previously published LC-MS/MS assay ([@bib21]). Detection of CPPIII serves as a biomarker for detecting coproporphyrinogen III, which is rapidly oxidized to CPPIII upon exposure to air during cell lysis and extraction ([@bib58]).

Fractionation of parasite-infected erythrocytes {#s4-7}
-----------------------------------------------

To assess whether parasites could synthesize heme from ALA in the absence of host enzymes in the erythrocyte cytoplasm, parasite-infected red blood cells were lysed with 0.05% saponin (0.2 µM filtered), spun briefly (3 min, 850×*g*) to pellet, washed in PBS, and resupended in 12 ml of RPMI/albumax growth media supplemented with 200 µM 5-\[^13^C~4~\]-ALA. Parasites were incubated overnight at 37°C, harvested by centrifugation, and extracted and analyzed by tandem mass spectrometry as described above.

Preparation of lysates from uninfected erythrocytes {#s4-8}
---------------------------------------------------

To assess the heme biosynthesis capacity of the erythrocyte cytoplasm, 500 µl packed red blood cells (described previously \[[@bib45]\]) were lysed in 20 ml of 0.04% saponin/PBS (0.2 µM filtered) and centrifuged at 25,000×*g* for 60 min to pellet unlysed cells and any organelles. The superficial 15 ml of the lysate supernatant was removed and 0.2 µM filtered, supplemented with 200 µM 5-\[^13^C~4~\]-ALA in the absence or presence of 50 µM SA, incubated overnight at 37°C, and analyzed by tandem mass spectrometry as described above.

Chemical block of parasite nutrient uptake pathways {#s4-9}
---------------------------------------------------

The 3D7 parasite line expressing the endogenous HSP101 from its genomic locus and bearing a C-terminal *Escherichia coli* DHFR degradation domain (DDD) fusion tag was previously published ([@bib3]). To test whether ALA uptake by parasite-infected erythrocytes depends on parasite-established nutrient-acquisition pathways in the host cell membrane, we split a synchronous culture of HSP101-DDD into two populations of late schizonts (purified over a magnetic column) and washed out TMP from one of the two cultures. Both cultures (±TMP) were permitted to lyse and reinvade fresh erythrocytes overnight. The following morning, parasites were placed in 200 µM ALA as early rings, incubated for 8 hr at 37°C, and imaged by live parasite microscopy as described above. Alternatively, asynchronous wild-type 3D7 parasites were incubated in the absence or presence of 100 µM furosemide for 1 hr to block nutrient-acquisition pathways, followed by the addition of 500 µM ALA and further incubation for 8 hr. Parasites were then imaged by live parasite microscopy as described above.

Antibodies and live cell stains {#s4-10}
-------------------------------

The following antibodies were used for IFM and WB analysis at the indicated dilutions: goat anti-GFP (Abcam 5450) (IFM 1:500, WB 1:1000), rabbit anti-ACP ([@bib57]; [@bib40]) (IFM: 1:500), Alexa Fluor 488-conjugated chicken anti-goat (IFM: 1:500), Alexa Fluor 555-conjugated donkey anti-rabbit (IFM: 1:500), donkey anti-goat-IRDye 800 (Licor Biosciences Geneva Lincoln, NE, USA) (WB: 1:10,000). MitoTracker Red was used at 50 nM final concentration and was added to parasite cultures 30 min prior to harvest and analysis.

Absorbance and luminescence spectroscopy {#s4-11}
----------------------------------------

Fluorescence excitation and emission spectra of pure PPIX in aqueous solution (excitation 400 nm, emission 620 nm) and of clarified lysates of *E. coli* bacteria expressing cobA (excitation 360 nm, emission 600 nm) and chemiluminescence spectra of luminol were obtained on a Cary Eclipse Fluorescence Spectrophotometer (Varian, Inc.) in either fluorescence or luminescence mode using 10-nm slit widths and a PMT detector voltage setting of 600. Luminol solutions contained 25 mM luminol in 100 mM NaOH (aq) to which 0.1% (wt/vol) ammonium persulfate (aq) was added to stimulate light emission.

Imaging hemozoin dynamics in parasite digestive vacuole {#s4-12}
-------------------------------------------------------

Time-lapse bright field images of parasites were acquired with 1 s delays, composed into video files using Adobe Photoshop, played back with 0.1 s delays between frames, and looped for 15 sec. Bright field images were acquired before and after 4 s image acquisitions with the Zeiss filter sets 38 (excitation 450--490 nm) and 43 HE (excitation 537--562 nm).

Homology models {#s4-13}
---------------

Homology models of PBGD and CPO were generated using the SWISS--MODEL interface on the Expasy website ([http://swissmodel.expasy.org](http://swissmodel.expasy.org/)). The template structures for modeling were human PBGD (PBD: 3EQ1) and human CPO (PDB: 2AEX).
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled "Deconvoluting Heme Biosynthesis to Target Blood-Stage Malaria Parasites" for peer review at *eLife*. Your submission has been favorably evaluated by Detlef Weigel (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The following individuals responsible for the peer review of your submission have agreed to reveal their identity: Jon Clardy (Reviewing editor); Emily Derbyshire (peer reviewer). A further reviewer remains anonymous.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors used 5-aminolevulinic acid (ALA), the product of the usual regulatory step in heme biosynthesis, to promote heme biosynthesis in the blood stage parasite. Using a variety of techniques they were able to show that while blood stage parasites do not usually synthesize heme, they can do so upon ALA stimulation. They also showed that host enzymes in the erythrocyte cytoplasm could complement genetic knockouts in the parasite\'s pathway. With ALA stimulation, a later step in heme biosynthesis become rate limiting, and the build-up of the redox active substrate for this step can inhibit parasite growth. The authors then devised a three-compoent mixture of ALA, luminol, and dihydroartemisinin that potently inhibited parasite growth when used in photodynamic therapy.

Essential revisions:

The reviewers were uniformly enthusiastic about the depth and completeness of the study on heme biosynthesis in the parasite, which utilized a number of techniques to provide a very complete description of the process. There were some concerns about its applied significance as the article points out that heme biosynthesis in the blood stage is normally a non-event, and the biosynthesis studied was prompted by providing a committed substrate, ALA. Please comment on the basic research advances and their relevance to normal malarial infections. In your response, it would be useful to also clarify how your results might, or might not, have been anticipated from earlier work.

The reviewers also appreciated the cleverness behind the development of the potent three-component treatment for photodynamic therapy of malaria with ALA, luminol, and dihydroartemisinin. But there were also concerns about the potential utility of this approach in a typical malaria setting, could you clarify how you think this would work. Toning down the immediate applicability of your findings might be appropriate. In your response to this it would be useful to see a dose response curve for ALA as the concentrations were quite high by usual therapeutic standards.

*Reviewer \#1*:

I need to begin by noting that my recent involvement with malaria research focused the liver stage, and that I am not very familiar with the extensive previous research on hemoglobin usage/synthesis in *Plasmodium*. As a result, my review may be off base.

This paper notes that while the parasite genome contains a complete heme biosynthetic pathway that appears to be essential for mosquito and liver stage growth, blood stage parasites with impaired heme biosynthesis show no growth defects because they can scavenge enough heme from the red blood cells they occupy. This manuscript focuses on the effects of stimulating heme biosynthesis in blood stage parasites through the addition of the key starting material 5-aminolevulinic acid (ALA). Formation of ALA is the rate-limiting step in heme biosynthesis, so added ALA bypasses normal heme biosynthetic regulation. This article focuses on two points: heme biosynthesis in infected red blood cells and a potential new therapeutic approach to treating malaria infections.

Heme biosynthesis: ALA-stimulated biosynthesis is observed even in erythrocytes infected with parasites in which key heme biosynthetic enzymes have been knocked out. The authors resolve this seeming paradox by establishing that host enzymes in the infected erythrocyte\'s cytoplasm can compensate the genetic knockouts. I believe that this finding is firmly established, but not very surprising.

Malaria therapy: Prior work had shown that ALA-stimulated biosynthesis leads to a new rate-limiting step and the accumulation of the starting material (PPIX) for this step. PPIX is fluorescent and this fluorescence has previously been used for following heme biosynthesis. The authors establish that parasites grown in 200 µM ALA fluoresce brightly. Prior work had also established that PPIX produced reactive oxygen species (ROS) when irradiated, and the cytotoxic effects of ROS generation has been exploited as a photodynamic therapy for cancer cells. In accord with this precedent, irradiation of parasite cultures treated with ALA displayed a significant growth defect. The authors explore the mechanism of growth inhibition in considerable detail and establish that host enzymes are largely responsible for PPIX formation and that parasites have an ALA uptake mechanism. They then go on to develop a photodynamic therapy for malaria using earlier findings about luminol enhancement from cancer chemotherapy and introducing artemisinin with its obvious relevance to malaria therapy. A three-component mixture of ALA, luminol, and dihydroartemisinin was potent in in vitro assays.

Overall, I\'m impressed with the thoroughness of the work, but I don\'t feel that any of the findings reach the level of significance usually found in *eLife* publications. In particular, I find the claims that this could lead to a useful therapeutic treatment for malaria to be inflated. The assays are in vitro, and the concentrations (100 µM ALA and 750 µM luminol) seem very high. The criteria for malaria therapies, which need to be effective in resource poor settings, include: single dose, low cost (preferably less than \$1), efficacy in all stages, and safety for pregnant women and children. Recently important articles on just such therapies have appeared (Nature) as have articles on significant host targets (Science). There is a high bar for innovative and useful malaria therapies. I\'m inclined to recommend against publication.

*Reviewer \#2*:

The manuscript by Sigala et al. uses a combination of state of the art biochemistry, gene disruption, metabolic LC/MS studies with 13C and cell imaging to dissect the heme biosynthesis pathway in *Plasmodium* erythrocytic stages and importantly to determine the contribution of parasite versus host red cell enzymes in the parasite biology. The authors show conclusively that the parasite heme biosynthesis is not essential through evaluation of several genetic knockouts in the pathway (e.g. porphbilinogen deaminase and cytosolic corproporphyrinogen III oxidase). They demonstrate that heme biosynthesis is stimulated by addition of exogenouse 5-aminolevulinic acids (ALA) and they show through fractionation and 13C labeling that host red cell enzymes and not parasite enzymes are responsible for metabolism of exogenous ALA to generate protoprphyrin IX (PPIX). They also show that parasite remodeling of the host cell is necessary to permeabilize the red cells to ALA uptake, thus there is also an important contribution of parasite expressed proteins to the ability of ALA to be utilized by the infected red cell. The identification of the role of red cell enzymes explains the paradox that *Plasmodium* ferrochelatase is essential while the upstream heme biosynthetic enzymes from the parasite are not. Finally they show that combinations of ALA, luminol and an activator such as artemesinin can be used to kill the parasites in vitro in the absence of light stimulation. (PPIX generates cytotoxic reactive oxygen species when photo-illuminated). Photodynamic therapy has been explored as a mechanism to kill cancer cells treated with ALA. As conventional photodynamic therapy would require a light source and not be practical for treatment of malaria, the authors used a combination of luminol activated by an oxygen radical generator (e.g. Artemisinin) to demonstrate that parasites are killed by these in combination with ALA.

This study very nicely solves the conundrum of heme biosynthesis in blood stage *Plasmodium*, demonstrating conclusively that it is not essential, that the parasites use instead salvaged heme, and demonstrating conclusively that stimulation of PPIX production in the presence of ALA is mediated by host cell enzymes. The described work is highly innovative and creative, and the logic of the approach is impressive, well-reasoned and well laid out in the manuscript. The work is very carefully done and uses a strong combination of approaches that lead to clear conclusive results. The possibility that photodynamic therapy might be used to treat malaria is also intriguing and the use of artemisinin as the oxygen radical source was very clever and novel. The study provides a mechanism for potentially rescuing the value of artemisinin even in "resistant" parasites. This paper clearly advances in a very significant way our understanding of heme biosynthesis in the malaria parasite and it provides a provocative potential new method for parasite treatment. The work is provocative and of excellent quality and I fully support its publication.

I have a few comments/questions that should be considered in the revision.

1\) Data described in the third paragraph of subsection "Development of chemiluminescence-based photodynamic therapy for treatment of blood-stage malaria". Were parasites in this study protected from light to ensure that there was no exogenous light induced activation of the killing mechanism?

2\) I think more could be said in the Discussion about the practicality of using photodynamic therapy in vivo, including a better sense of if this method has worked in vivo for cancer. In the fifth paragraph of the Discussion they state that ALA and luminol have good toxicity profiles, but what about the PK and oral bioavailbility profiles, is there any data to address if these profiles would be suitable for malaria therapy?

3\) In the fourth paragraph of the Discussion, it should be clarified whether or not the authors think 0.2 uM exogenous ALA would be sufficient to induce light induced killing? Particularly given the use of 100 - 200 uM in their studies. Was any dose titration done to determine the lowest level of ALA that could be used for light induced killing? How was the dose of ALA chosen for the studies?

*Reviewer \#3*:

In the manuscript entitled "Deconvoluting Heme Biosynthesis to Target Blood Stage Malaria Parasites" Sigala et al. use biochemical, genetic and chemical methods to unravel the role of heme biosynthesis in blood stage malaria. Their work demonstrates that heme biosynthesis de novo is dispensable for parasite viability, but can occur after addition of the heme precursor ALA using enzymes in both the parasite and host erythrocyte. The latter being particularly interesting since mature red blood cells lose part of their heme biosynthesis pathway when they expel their mitochondria. The manuscript determines that parasites enable the uptake of ALA into the erythrocyte with established new permeability pathways and demonstrate that the combination of luminol and ALA is lethal. This interesting work will greatly contribute to the current body of literature on *Plasmodium* heme biosynthesis and presents a novel malaria treatment strategy.

The manuscript clearly explains how their proposed luminol/ALA combination therapy would target a host process and therefore may not lead to parasite drug resistance. Since this process relies on host processes it also seems likely that such a strategy would be effective against multiple human-infective parasite species. While the authors do not test this it might be worth mentioning in the Discussion.

*Minor comments*:

1\) It might be helpful to readers to indicate on the heme biosynthesis schematic ([Figure 1A](#fig1){ref-type="fig"}) that SA inhibits ALAD.

2\) In the third paragraph of the Discussion it is mentioned that human serum contains 100 - 200 nM ALA and there is data that suggests that this low level is enough to stimulate heme biosynthesis. Based on [Figure 7B](#fig7){ref-type="fig"} this amount does not seem like it is enough to be toxic with luminol addition. For many experiments in this work 200 uM ALA was added to the cultures and is sufficient to induce toxicity. It would be interesting to know the lower limit of ALA addition that can induce toxicity if it was determined.

10.7554/eLife.09143.035

Author response

*The reviewers were uniformly enthusiastic about the depth and completeness of the study on heme biosynthesis in the parasite, which utilized a number of techniques to provide a very complete description of the process. There were some concerns about its applied significance as the article points out that heme biosynthesis in the blood stage is normally a non-event, and the biosynthesis studied was prompted by providing a committed substrate, ALA. Please comment on the basic research advances and their relevance to normal malarial infections. In your response, it would be useful to also clarify how your results might, or might not, have been anticipated from earlier work*.

Genome sequencing has been enormously helpful in identifying the metabolic pathways potentially used by *Plasmodium* parasites to survive and proliferate within human erythrocytes and which might serve as new therapeutic targets. Nevertheless, metabolic maps resulting from gene annotation are only a model, and a full understanding of parasite metabolism and the therapeutic potential of individual pathways requires direct genetic and biochemical dissection that goes well beyond knocking out individual genes or testing the effects of inhibitors assumed to be specific based on studies in other organisms.

Our work clarifies that the parasite heme biosynthesis pathway, despite expression of all pathway enzymes, is non-functional during blood-stage infection and that porphyrin biosynthesis activity by parasite-infected erythrocytes arises almost entirely from host enzyme activity in the red cell cytoplasm. This surprising result could not have been anticipated from prior works (e.g., Sigala 2014, van Dooren 2012, Surolia 1992, Ke 2014, Nagaraj 2013), all of which have assumed activity by the parasite heme biosynthesis pathway in blood stages.

Although the remnant host enzymes are normally inactive in uninfected erythrocytes, due to lack of the ALA substrate resulting from the absence of mitochondrial ALAS as well as erythrocyte impermeability to low-level serum ALA, our data suggests that this host-derived pathway can be active in the context of a parasite-infected erythrocyte, whose enhanced permeability enables uptake of ∼0.2 µM serum ALA. This low-level ALA is likely sufficient to stimulate modest heme biosynthesis in the parasite mitochondrion, where the parasite ferrochelatase can insert iron into the PPIX synthesized from host enzyme activity (see [Figure 4](#fig4){ref-type="fig"}). Our work thus clarifies the fundamental mechanism of heme biosynthesis in parasite-infected erythrocytes, which reflects the concerted activity of ALA-stimulated host enzymes plus the parasite ferrochelatase.

Most drug discovery studies focus nearly exclusively on the suitability of a metabolic pathway for therapeutic inhibition. If a pathway is not essential then it is usually not pursued as a drug target. Though heme biosynthesis is not an essential pathway for blood-stage parasites (Ke 2014, Nagaraj 2013), our manuscript shows that this pathway is nonetheless targetable because stimulation of pathway activity can be exploited to kill parasites. The success of our strategy could not have been anticipated from earlier work, as recent work (Ke 2014, Nagaraj 2013) concluded that this pathway was not a druggable target.

In summary, our detailed study combining both genetic and metabolic dissection has both clarified basic biochemical activity and mechanism of a fundamental biosynthetic pathway and suggested the potential for a novel form of antimalarial therapy. We have modified the Discussion to clarify these points.

*The reviewers also appreciated the cleverness behind the development of the potent three-component treatment for photodynamic therapy of malaria with ALA, luminol, and dihydroartemisinin. But there were also concerns about the potential utility of this approach in a typical malaria setting, could you clarify how you think this would work. Toning down the immediate applicability of your findings might be appropriate*.

Dihydroartemisinin (DHA) is already in clinical use for treatment of blood-stage malaria. We envision a combination therapy in which appropriate ALA and luminol doses are delivered orally with DHA. As for any new therapy, extensive additional studies in animals and humans will be required to optimize treatment regimens for our proposed therapy and to confirm efficacy and safety in vivo. We expound on these points below in responses to specific Reviewer points. We have modified the Discussion to clarify that additional in vivo studies will be required to further test and optimize our proposed therapy for clinical use.

*In your response to this it would be useful to see a dose response curve for ALA as the concentrations were quite high by usual therapeutic standards*.

As noted below in our response to Reviewer \#3 (point 2), we have now inserted an ALA-dose response curve for parasite photosensitivity as [Figure 1--figure supplement 3](#fig1s3){ref-type="fig"}.

With respect to "therapeutic standards", we note that the 10-100 µM ALA used herein (e.g., [Figure 7B](#fig7){ref-type="fig"} and [7C](#fig7){ref-type="fig"} and [Figure 1--figure supplement 3](#fig1s3){ref-type="fig"}) is well within ALA concentrations that have been tested systemically in vivo in humans for clinical photodynamic therapy and that appear to be well tolerated. Indeed, plasma ALA concentrations ∼10 µM can be obtained in humans by a single oral dose of 100 mg ALA, which is well below the 40-50 mg/kg doses of ALA that have been used clinically with minimal side effects. These pharmacokinetic properties are explored in J Pharmacol Exp Ther 2002: 507-512, Photochem Photobiol 2001: 339-345, and references therein, and we now cite these references in the Discussion section.

Reviewer \#1:

*\[...\] Overall, I\'m impressed with the thoroughness of the work, but I don\'t feel that any of the findings reach the level of significance usually found in* eLife *publications. In particular, I find the claims that this could lead to a useful therapeutic treatment for malaria to be inflated. The assays are in vitro, and the concentrations (100 µM ALA and 750 µM luminol) seem very high. The criteria for malaria therapies, which need to be effective in resource poor settings, include: single dose, low cost (preferably less than \$1), efficacy in all stages, and safety for pregnant women and children. Recently important articles on just such therapies have appeared (Nature) as have articles on significant host targets (Science). There is a high bar for innovative and useful malaria therapies. I\'m inclined to recommend against publication*.

Please see our responses above (Essential revisions) and below to Reviewer \#2 (point 2) and reviewer \#3 (point 2).

Reviewer \#2:

*1) Data described in the third paragraph of subsection "Development of chemiluminescence-based photodynamic therapy for treatment of blood-stage malaria"*. *Were parasites in this study protected from light to ensure that there was no exogenous light induced activation of the killing mechanism?*

We minimized the exposure of parasite cultures to ambient light by changing media within darkened TC hoods and covering parasite culture dishes during brief (5-10 sec.) transits to and from incubators. As shown in [Figure 7B](#fig7){ref-type="fig"} and [7C](#fig7){ref-type="fig"}, this low level of light exposure was insufficient to activate phototoxicity in the ALA-only control culture. We have clarified this point in the Methods.

*2) I think more could be said in the Discussion about the practicality of using photodynamic therapy in vivo, including a better sense of if this method has worked in vivo for cancer. In the fifth paragraph of the Discussion they state that ALA and luminol have good toxicity profiles, but what about the PK and oral bioavailbility profiles, is there any data to address if these profiles would be suitable for malaria therapy*?

There is an extensive literature regarding the use and efficacy of photodynamic therapy (PDT) for treatment of cancer, including use of ALA as a photosensitizer. We refer the reviewer and interested readers to Kennedy 1990 and Celli 2010 and Photochem Photobiol Sci 2007:1234-1245, which discuss PDT and its application for cancer therapy in depth, and to references therein. Bioavailability and PK data for systemic use of ALA and luminol are available in the literature (e.g., J Pharmacol Exp Ther 2002: 507-512, Molecules 2011: 4140-4164, Photochem Photobiol 2001: 339-345, reference 49, and references therein) including data to suggest that ALA doses sufficient to attain serum concentrations in the range explored in vitro herein persist for several hours in the blood-stream and show little associated toxicity (see also responses to Essential Revisions above).

As for any new therapy suggested by in vitro studies, extensive additional studies in animals and humans will be required to optimize treatment regimens for our proposed therapy and to confirm efficacy and safety in vivo. We have plans to carry out these experiments, beginning with in vivo studies with the mouse malaria parasite, *P. berghei.* The results of these studies will be the subject of future manuscripts, as they extend well beyond the scope of the present study. Our goals in this manuscript were first and foremost to clarify the basic biochemical mechanisms and properties of heme biosynthesis in *Plasmodium*-infected erythrocytes and secondarily to explore whether ALA-stimulated porphyrin biosynthesis could be harnessed to target blood-stage malaria. Our results herein using artemisinin and chemiluminescence-based photodynamic therapy show outstanding promise in vitro, and we are moving forward to test this strategy in vivo.

We have inserted the additional references noted above regarding the use of PDT for cancer treatment and the bioavailability and PK features of ALA and luminol. We have also modified the Discussion to clarify that additional in vivo studies will be required to further test and optimize our proposed therapy for clinical use.

*3) In the fourth paragraph of the Discussion, it should be clarified whether or not the authors think 0.2 uM exogenous ALA would be sufficient to induce light induced killing? Particularly given the use of 100 - 200 uM in their studies. Was any dose titration done to determine the lowest level of ALA that could be used for light induced killing? How was the dose of ALA chosen for the studies*?

Please see our response below to Reviewer \#3, point 2.

Reviewer \#3:

*\[...\] The manuscript clearly explains how their proposed luminol/ALA combination therapy would target a host process and therefore may not lead to parasite drug resistance. Since this process relies on host processes it also seems likely that such a strategy would be effective against multiple human-infective parasite species. While the authors do not test this it might be worth mentioning in the Discussion*.

We agree with the reviewer that our proposed therapy may be active against other pathogens that infect human erythrocytes, such as *Babesia*. Because ALA uptake requires enhanced erythrocyte permeability upon parasite infection, it remains a future challenge to test whether other intraerythrocytic parasites like *Babesia* also alter host cell permeability in a manner that enables ALA uptake. We have followed the reviewer's suggestion and have modified the Discussion section to propose that chemiluminescence-based photodynamic therapy may be active against other parasites that infect erythrocytes.

Minor comments:

*1) It might be helpful to readers to indicate on the heme biosynthesis schematic (*[*Figure 1A*](#fig1){ref-type="fig"}*) that SA inhibits ALAD*.

We thank the reviewer for this suggestion. We have modified both [Figure 1A](#fig1){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"} to indicate that succinylacetone inhibits ALAD.

*2) In the third paragraph of the Discussion it is mentioned that human serum contains 100 - 200 nM ALA and there is data that suggests that this low level is enough to stimulate heme biosynthesis. Based on* [Figure 7B](#fig7){ref-type="fig"} *this amount does not seem like it is enough to be toxic with luminol addition. For many experiments in this work 200 uM ALA was added to the cultures and is sufficient to induce toxicity. It would be interesting to know the lower limit of ALA addition that can induce toxicity if it was determined*.

We looked at the ALA dose-dependence of photosensitivity by parasites. Parasite death and culture growth inhibition in the presence of light was detectable in ALA concentrations as low as 5-10 µM, although full or nearly full growth inhibition required ALA concentrations greater than 50 µM. We have added this data as [Figure 1--figure supplement 3](#fig1s3){ref-type="fig"}.
